carbonic acid 2,5-dioxo-pyrrolidin-1-yl ester isopropyl ester | 152685-13-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: carbonic acid 2,5-dioxo-pyrrolidin-1-yl ester isopropyl ester
• 英文别名: 1-{[(propan-2-yloxy)carbonyl]oxy}pyrrolidine-2,5-dione；2,5-Dioxo-1-pyrrolidinyl 1-methylethyl carbonate；(2,5-dioxopyrrolidin-1-yl) propan-2-yl carbonate
• CAS: 152685-13-7
• 化学式: C₈H₁₁NO₅
• 分子量: 201.179
• InChiKey: MKFSKYXMDOZQOQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  72.9
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  carbonic acid 2,5-dioxo-pyrrolidin-1-yl ester isopropyl ester 、 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 以38 mg的产率得到
  参考文献：
  名称：

  Discovery of Hepatitis C Virus NS3-4A Protease Inhibitors with Improved Barrier to Resistance and Favorable Liver Distribution

  摘要：

  Given the emergence of resistance observed for the current clinical-stage hepatitis C virus (HCV) NS3 protease inhibitors, there is a need for new inhibitors with a higher barrier to resistance. We recently reported our rational approach to the discovery of macrocyclic acylsulfonamides as HCV protease inhibitors addressing potency against clinically relevant resistant variants. Using X-ray crystallography of HCV protease variant/inhibitor complexes, we shed light on the complex structural mechanisms by which the D168V and R155K residue mutations confer resistance to NS3 protease inhibitors. Here, we disclose SAR investigation and ADME/PK optimization leading to the identification of inhibitors with significantly Unproved potency against the key resistant variants and with increased liver partitioning.

  DOI：

  10.1021/jm400121t

文献信息

• [EN] OXAZEPINE DERIVATIVES HAVING TNAP INHIBITORY ACTIVITY<br/>[FR] DÉRIVÉS D'OXAZÉPINE AYANT UNE ACTIVITÉ INHIBITRICE DE TNAP
  申请人：DAIICHI SANKYO CO LTD

  公开号：WO2018119449A1

  公开（公告）日：2018-06-28

  The present invention relates to a compound or a pharmacologically acceptable salt thereof having excellent tissue non-specific alkaline phosphatase inhibitory activity. The present invention provides a compound represented by the formula (I) or a pharmacologically acceptable salt thereof.

  本发明涉及一种具有优异的组织非特异性碱性磷酸酶抑制活性的化合物或其药理学上可接受的盐。本发明提供一种由式(I)表示的化合物或其药理学上可接受的盐。
• FUNCTIONALIZED PEGYLATED CYANINE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF
  申请人：BroadPharm

  公开号：US20170197916A1

  公开（公告）日：2017-07-13

  Provided herein are functionalized pegylated cyanine compounds containing a reactive group suitable for labeling a biomolecule or pharmaceutical compositions and methods of use thereof. In one embodiment, the compounds are based on formula I shown below. In other embodiments, the compounds can be pegylated at one or more of the following locations R 1 , R 4 , R 6 , R 9 , or L.

  本文提供了含有适用于标记生物分子或药物组合物的反应性基团的功能化聚乙二醇化青霉素化合物，以及其使用方法。在一种实施方式中，该化合物基于下面所示的I式。在其他实施方式中，该化合物可以在以下位置之一或多个位置进行聚乙二醇化：R1、R4、R6、R9或L。
• METHODS TO INCREASE THE PHOTOSTABILITY OF DYES
  申请人：Hahn Klaus

  公开号：US20110046000A1

  公开（公告）日：2011-02-24

  The presently disclosed subject matter provides dyes having an improved photostability, biosensors comprising such dyes, and methods of use thereof, including methods for detecting target molecules in a sample under test and for live-cell imaging. The dyes can include a binding member, including a biomolecule or fragments thereof, which can interact with target molecules of interest and can be specific to a given conformational state or covalent modification, e.g., phosphorylation, of the target molecule. The presently disclosed dyes can be used for detecting changes in the binding, conformational change, or posttranslational modification of the target molecule.

  所述主题提供了具有改善光稳定性的染料、包括此类染料的生物传感器以及其使用方法，包括用于检测样品中的靶分子和用于活细胞成像的方法。该染料可以包括结合成员，包括生物分子或其片段，其可以与感兴趣的靶分子相互作用，并且可以特定于给定的构象状态或靶分子的共价修饰，例如磷酸化。目前披露的染料可用于检测靶分子的结合、构象变化或后翻译修饰的变化。
• Resistance-repellent retroviral protease inhibitors
  申请人：Sequoia Pharmaceuticals, Inc.

  公开号：EP2422781A1

  公开（公告）日：2012-02-29

  Resistance-repellent and multi-drug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.

  提供了抗药性和多重抗药性逆转录病毒蛋白酶抑制剂。还提供了包含此类化合物的药物组合物，以及使用此类化合物治疗哺乳动物艾滋病毒感染的方法。
• Eight-arm polyethylene glycol derivative, production method therefor, and modified bio-related substance thereof
  申请人：Xiamen Sinopeg Biotech Co., Ltd.

  公开号：US10660969B2

  公开（公告）日：2020-05-26

  Disclosed are an 8-arm polyethylene glycol (PEG) derivative (formula 1), manufacturing method and modified bio-related substance thereby, wherein a tetravalent group U and four trivalent groups Ec form a highly symmetric octavalent central structure CORE0 together, Lc connects the octavalent center to eight PEG arms having polydiversity or monodiversity and having n1-n8 as the degrees of polymerization thereof. The terminal of one PEG chain is connected to at least one functional group F (k≥1), and said PEG chain and F can be directly connected (g=0) or connected with a divalent linking group L0 connected with a terminal branched group G (g=1) therebetween. The latter provides more reacting sites to combine more pharmaceutical molecules, thereby increasing the drug loading capacity. The near-center symmetric structure of the derivative allows more precise control over the molecular weight during large-scale production, thereby facilitating acquisition of a product having a narrower molecular weight distribution. A bio-related substance modified thereby has a more uniform and controllable performance.

  本发明公开了一种 8 臂聚乙二醇（PEG）衍生物（式 1）、其制造方法和改性生物相关物质，其中一个四价基团 U 和四个三价基团 Ec 共同形成一个高度对称的八价中心结构 CORE0，Lc 将八价中心连接到八个 PEG 臂上，这些 PEG 臂具有多元性或单元性，其聚合度为 n1-n8。一条 PEG 链的末端与至少一个官能团 F（k≥1）相连，所述 PEG 链和 F 可以直接相连（g=0），也可以通过二价连接基 L0 与末端支化基 G（g=1）相连。后者提供了更多的反应位点，可结合更多的药物分子，从而提高药物负载能力。衍生物的近中心对称结构可以在大规模生产过程中更精确地控制分子量，从而有利于获得分子量分布更窄的产品。由此改性的生物相关物质具有更均匀、更可控的性能。